Drug Development Pharma - March 10, 2015
Health Canada OKs Weight Drug
Health Canada has approved the new drug submission for Novo Nordisk’s Saxenda® (liraglutide), the first once-daily human glucagon-like peptide-1 (GLP-1) analogue for the treatment of chronic weight management. Saxenda® is an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in obese adults and overweight adults with at least one […]